Keywords
Diabetes Mellitus Type 2
Essential Hypertension
Cardiovascular Diseases
Neoplasms
Sleep Apnea Obstructive
Osteoarthritis
Metabolic Syndrome
Obesity Management
Anti-Obesity Agents
How to Cite
Abstract
Obesity is a conditioning factor for the development of pathologies such as: type 2 diabetes mellitus, arterial hypertension, dyslipidemias, respiratory sleep disorders, cardiovascular conditions and increased risk of cancer. In Colombia, about 56.4 % of the population is overweight. For this reason, between October 15, 2022 and January 31, 2023, a review of the subject was carried out in the Scielo and Pubmed/Medline databases, divided into two parts: the first, focused on the pathophysio- logical relationship of pathologies such as arterial hypertension, diabetes mellitus, cancer, among others, and obesity; the second, aimed at establishing the appropriate approach to obesity, including pharmacological and non-pharmacological measures. This review seeks to highlight the importance of a comprehensive approach to patients with obesity, empha- sizing the importance of its identification as a risk factor or trigger for various metabolic and cardiovascular conditions.
References
Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: Pathophysiology and Management. J Am Coll Cardiol. 2018;71(1):69-84.
Instituto Colombiano de Bienestar Familiar (ICBF). ENSIN: Encuesta Nacional de la Situación Nutricional. Bogotá, Colombia. Portal ICBF. 2015. https://www.icbf.gov.co/bienestar/nutricion/ encuesta-nacional-situacion-nutricional.
Jaganathan R, Ravindran R, Dhanasekaran S. Emerging Role of Adipocytokines in Type 2 Diabetes as Mediators of Insulin Resistance and Cardiovascular Disease. Can J Diabetes. 2018;42(4):446-456.
Løvsletten O, Jacobsen BK, Grimsgaard S, Njølstad I, Wilsgaard T, Løchen ML, et al. Prevalence of general and abdominal obesity in 2015-2016 and 8-year longitudinal weight and waist circumference changes in adults and elderly: the Tromsø Study. BMJ Open. 2020;10(11).e038465.
Wensveen FM, Valentić S, Šestan M, Turk Wensveen T, Polić B. The “Big Bang” in obese fat: Events initiating obesity-induced adipose tissue inflammation. Eur J Immunol. 2015;45(9):2446- 2456.
Vega-Robledo GB, Rico-Rosillo MG. Tejido adiposo: función inmune y alteraciones inducidas por obesidad. Rev. alerg. Méx. 2019;66(3):340– 353.
Johnson AR, Milner JJ, Makowski L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev. 2012;249(1):218-238.
Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens. 2013;15(1):14-33.
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991-1006.
Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017; 122:1-7.
Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98-107.
Al-Kaisey AM, Kalman JM. Obesity and atrial fibrillation: Epidemiology, Pathogenesis and Effect of Weight Loss. Arrhythm Electrophysiol Rev. 2021; 10(3):159-164.
Stender S, Nordestgaard BG, Tybjaerg-Hansen A. Elevated body mass index as a causal risk factor for symptomatic gallstone disease: a Mendelian randomization study. Hepatology. 2013; 58(6):2133-2141.
Stokes CS, Lammert F. Excess Body Weight and Gallstone Disease. Visc Med. 2021; 37(4): 254– 260.
Steele CB, Thomas CC, Henley SJ, Massetti GM, Galuska DA, Agurs-Collins T, et al. Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity — United States, 2005–2014. MMWR Morb Mortal Wkly Rep. 2017;66(39):1052–1058.
Keum N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, et al. Adult weight gain and adiposity- related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst. 2015;107(2).
Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15(8):484– 498.
Meurling IJ, Shea DO, Garvey JF. Obesity and sleep. Curr Opin Pulm Med. 2019;25(6):602–608.
Páez-Moya S, Vega-Osorio PA. Factores de riesgo y asociados al síndrome de apnea-hipopnea obstructiva del sueño (SAHOS). Rev Fac Med Univ Nac Colomb. 2017;65(1Sup):21–24.
ACR: american college of rheumatology [Internet]. Atlanta, Estados Unidos. Osteoartitis: 2019 Mar; [3]. Disponible en: https://rheumatology.org/patients/osteoartritis
Sellam J, Berenbaum F. Is osteoarthritis a metabolic disease?. Joint Bone Spine. 2013;80(6):568-573.
Mayer SB, Graybill S, Raffa SD, Tracy C, Gaar E, Wisbach G, et al. Synopsis of the 2020 U.S. VA/DoD Clinical Practice Guideline for the Management of Adult Overweight and Obesity. Mil Med. 2021;186(9-10):884-896.
Obesity Management Task Force of the European Association for the Study of Obesity. European Guidelines for Obesity Management in Adults. Alemania. Karger;2015. https://doi.org/10.1159/000442721
Canadian clinical practice guideline. Obesity in adults: a clinical practice guideline. Canadá.CMAJ;2020. https://doi.org/10.1503/cmaj.191707
Wadden T, Tronieri J, Butryn M. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75(2):235-251.
The obesity Society with de ACC/AHA Task force. Guidelines (2013) for managing overweight and obesity in adults. Estados Unidos. Obesity; 2014. https://doi.org/10.1002/oby.20818.
Gotthelf L, Chen YT, Rajagopalan S, Wu EC, Doshi I, Addy C. High intensity lifestyle intervention and long-term impact on weight and clinical outcomes. PLoS One. 2018;13(4).
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6): 393-403.
Butryn ML, Webb V, Wadden TA. Behavioral treatment of obesity. Psychiatr Clin North Am. 2011;34(4):841-859.
Kushner RF. Weight Loss Strategies for Treatment of Obesity. Lifestyle Management and Pharmacotherapy. Prog Cardiovasc Dis. 2018;61(2):246-252.
McCafferty BJ, Hill JO, Gunn AJ. Obesity: Scope, Lifestyle Interventions, and Medical Management. Tech Vasc Interv Radiol. 2020;23(1).
Thom G, Lean M. Is there an optimal diet for weight management and metabolic health? Gastroenterology. 2017;152(7):1739–1751.
Duque J, Rosero R, Asociación Colombiana de Endocrinología, Diabetes y Metabolismo. Recomendaciones de la Asociación Colombiana de Endocrinología, Diabetes y Metabolismo para el Manejo de la Obesidad. 2023. https://www. endocrino.org.co/sites/default/files/2022-08/Rec.%20Obesidad%20Vol.1.pdf
Webb V, Wadden T. Intensive Lifestyle Intervention for Obesity: Principles, Practices, and Results. Gastroenterology. 2017;152(7):1752– 1764.
Lucas K, Kaplan-Machlis B. Orlistat — a novel weight loss therapy. Annals of Pharmacotherapy. 2001;35(3),314–328.
Kelly A, Auerbach P, Barrientos-Perez M, Gies I, Hale P, Marcus C et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;28;382(22):2117-2128.
Wilding J, Batterham R, Calanna S, Davies M, Van Gaal L, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
Jastreboff A, Aronne L, Ahmad N, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Médicas UIS